Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature
Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature
复制标题
DOI：
10.1038/hr.2009.139
复制
发表时间：
2009-11-01
影响因子：
5.4
通讯作者：
Wang, Jiguang
中科院分区：
文献类型：
--
作者：
Liu, Lisheng;Wang, Zengwu;Wang, Jiguang
在一项双盲安慰剂对照试验中，我们评估了降低血压（BP）是否可以预防中国脑血管疾病患者中风的复发。患者被随机分为两组：2825名患者接受安慰剂治疗，2840名患者每天接受2.5 mg吲达帕胺治疗。主要和次要结局分别是致死性或非致死性卒中的复发以及主要致死性和非致死性心血管事件的复发。随机分组时的平均收缩压/舒张压为153.8/92.8 mmHg。在中位随访（2年）中，积极治疗患者的血压平均降低6.8/3.3mmHg。总共有143名吲达帕胺组患者和219名安慰剂组患者发生卒中复发(吲达帕胺组的风险比为0.69；95%可信区间（CI）： 0.54-0.89；P
We assessed, in a double-blind, placebo-controlled trial, whether lowering blood pressure (BP) prevents the recurrence of stroke in Chinese patients with cerebrovascular disease. Patients were randomized into two groups: 2825 patients received a placebo and 2840 patients received 2.5 mg of indapamide daily. The primary and secondary outcomes were the recurrence of fatal or nonfatal stroke and major fatal and nonfatal cardiovascular events, respectively. The average systolic/diastolic BP at randomization was 153.8/92.8 mm Hg. At median follow-up (2 years), BP was, on an average, 6.8/3.3mmHg lower in patients on active treatment. In total, 143 patients on indapamide and 219 patients on placebo had recurrent strokes (hazard ratio for indapamide, 0.69; 95% confidence interval (CI): 0.54-0.89; P